Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion

Annals of Oncology

Volumn 10, Issue 3, 1999, Pages 339-344

  Stevenson, J P ^a,f   DeMaria, D ^b   Sludden, J ^c   Kaye, S B ^c   Paz Ares, L ^c   Grochow, L B ^d   McDonald, A ^c   Selinger, K ^e   Wissel, P ^e   O'Dwyer, P J ^a,b   Twelves, C ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e GLAXOSMITHKLINE   (United States)

^f PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Camptothecin analogues; Continuous infusion; GG211; Phase I trial; Topoisomerase I inhibitors

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; LURTOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0032956196     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008313011289     Document Type: Article

References (32)

1. Hsiang Y-H. Hertzberg R, Hecht S et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8.
2. Wang JC. DNA topoisomerases. Ann Rev Biochem 1985; 54: 665-97.
3. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
4. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 1988; 85: 7501-5.
5. Giovanella BC, Stehlin JS, Wall ME et al. DNA topoisomerase I targeted chemotherapy of human colon cancer xenografts. Science 1989; 246: 1046-50.
6. Husain I, Mohler JL, Seigler HF et al. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54: 539-46.
7. Muggia FM, Creaven PJ, Hansen HH et al. Phase I trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515-21.
8. Emerson DL, Besterman JM, Brown HR et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 1995; 55: 603-9.
9. Luzzio MJ, Besterman JM, Emerson DL et al. Synthesis and antitumor activity of novel water-soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 1995; 38: 395-401.
10. Emerson DL, Vuong A, McIntyre G et al. In vivo efficacy of two new water-soluble camptothecin analogs in the human cancer xenograft model. Proc Am Assoc Cancer Res 1993; 34: 419 (Abstr).
11. Burris III HA, Hanauske A-R, Johnson RK et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84: 1816-20.
12. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9.
13. Hochster H, Speyer J, Wadler S et al. Activity of topotecan (TPT) 21-day infusion inplatinum treated ovarian cancer and pharmacodynamics of topo-1 depletion (A NYGOG study). Proc Eur Soc Med Oncol 1996; 21: 69 (Abstr).
14. Paz-Ares L, Kunka R, DeMaria D et al. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-hour continuous infusion. Br J Cancer 1998; in press.
15. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
16. Selinger K, Smith G, Depee S et al. Determination of GI147211 in human blood by HPLC with fluorescence detection. J Pharm Biomed Anal 1995; 13: 1521-30.
17. Gibaldi M, Perrier D. Nonlinear pharmacokinetics. In Gibaldi M, Perrier D (ed): Pharmacokinetics. New York: Marcel Dekker 1984; 271-84.
18. Houghton PJ, Cheshire PJ, Hallman JC et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4[1-piperidino]-1-piperidino)-carbonyloxycamptothecin against human tumor xenografts: Lack of cross-resistance in vivo tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-camptothecin. Cancer Res 1993; 53: 2823-9.
19. Gerrits CJH, Creemers GJ, Schellens JHM et al. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration. Br J Cancer 1996; 73: 744-50.
20. Gerrits CJH, Schellens JH, Creemers GJ et al. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br J Cancer 1997; 76: 946-51.
21. van Oosterom AT, Gore M, Calvert AH et al. Activity of GW211 (GI147211) in relapsed ovarian cancer, a phase II study. Proc Am Soc Clin Oncol 1997; 16: 349a (Abstr).
22. Heinrich B, Lehnert M, Cavalli Fetal. Phase II trial of GI147211 in locally advanced or metastatic non-small cell lung cancer (NSCLC): An EORTC-ECSG trial. Proc Am Soc Clin Oncol 1997; 16: 470a (Abstr).
23. Wanders J, ten Bokkel-Huinink WW, Heinrich B et al. Phase II studies with GI-147211 in five different tumor types - preliminary results. Ann Oncol 1996; 7 (Supp 1): 131 (Abstr).
24. Wanders J, ten Bokkel-Huinink WW, Pavlidis N et al. Phase II studies with GI147211 (GI) in breast (B), colorectal (C) and non-small-cell lung cancer. Eur J Cancer 1997; 33 (Suppl 8): S158 (Abstr).
25. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
26. Comis RL. Oral etoposide in oncology: An evolving role. Ann Oncol 1992; 3: 63-7.
27. Danks MK, Pawlik CA, Whipple DO et al. Intermittent exposure of medulioblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Clin Cancer Res 1997; 3: 1731-8.
28. Stevenson JP, Scher RM, Kosierowski R et al. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998; 34: 1358-62.
29. Hochster H, Ibrahim J, Liebes L et al. Phase II study of 21-day topotecan continuous infusion for metastatic colorectal cancer (ECOG study 4293). Proc Am Soc Clin Oncol 1997; 16: 290a (Abstr).
30. Creemers GJ, Gerrits CJH, Schellens JHM et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996; 14: 2540-5.
31. Mainwaring PM, Nicolson MC, Hickish T et al. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: No evidence of increased efficacy. Br J Cancer 1997; 76: 1636-9.
32. Emerson DL, Amirgahari N, Bendele R et al. NX-211, a liposomal formulation of lurtotecan demonstrates enhanced pharmacokinetic and antitumor activity. Proc Am Assoc Cancer Res 1998; 39: 278 (Abstr).